1060 SURVIVIN EXPRESSING CIRCULATING TUMOR CELLS IN NON-MUSCHE INVASIVE BLADDER CANCER A CELLECTION™ DYNABEADS ANALYSIS

Abstract

You have accessJournal of UrologyBladder Cancer: Basic Research III1 Apr 20121060 SURVIVIN EXPRESSING CIRCULATING TUMOR CELLS IN NON-MUSCHE INVASIVE BLADDER CANCER A CELLECTION™ DYNABEADS ANALYSIS Gian Maria Busetto, Arianna Petracca, Chiara Nicolazzo, Paola Gazzaniga, Vincenzo Gentile, and Ettore De Berardinis Gian Maria BusettoGian Maria Busetto Roma, Italy More articles by this author , Arianna PetraccaArianna Petracca Roma, Italy More articles by this author , Chiara NicolazzoChiara Nicolazzo Roma, Italy More articles by this author , Paola GazzanigaPaola Gazzaniga Roma, Italy More articles by this author , Vincenzo GentileVincenzo Gentile Roma, Italy More articles by this author , and Ettore De BerardinisEttore De Berardinis Roma, Italy More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1166AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The prognosis of T1G3 bladder cancer is highly ariable and not predictable basing upon clinical and pathological prognostic factors. There is need for improvement in risk stratification in this population; understanding the molecular profile of individual patients could provide a more personalized and tailored treatment. Main objective was to evaluate the prognostic significance of Survivin in tumor tissues and that of Survivin expressing circulating tumor cells (CTCs) in T1G3 tumors. METHODS 161 patients with T1G3 non muscle invasive bladder cancer (NMIBC), including CIS associated, were enrolled. Planned follow up was 24 mo. Survivin was evaluated by RT-PCR in tumoral tissues. CTCs were isolated from blood by CELLection™ dynabeads coated with the monoclonal antibody towards the human Epithelial Cell Adhesion Molecule. Cells were lysed and Dynabeads Oligo(dT) was used to capture poly A+ mRNA. cDNA was synthesised and analysed for the expression of CD45, CK8 and Survivin. The primary end point was disease free survival (DFS); the favourable group at 24 mo was defined as that without any clinical evidence of disease (NED); the unfavourable group was that with evidence of recurrent disease (RD) or progressive disease (PD). Tumour survivin expression and presence of CTC were correlated with DFS. Multivariate analysis was used to investigate whether the presence of CTC was an independent indicator of DFS. RESULTS Survivin was found in about 50% of tumors. Survivin-patients showed a longer DFS than Survivin + tumors (X2=6.222, p=0.019). CTCs were found in 84/161 patients (52%); 96% of CTC were Survivin expressing. The difference in DFS between CTC - and CTC + patients was statistically significant (X2=29.565; p=0.001). CTC presence was found an independent prognostic factor of DFS (p=0.001). CONCLUSIONS To date, for bladder cancer, there is the lack of a realible marker able to predict the prognosis and with the capability to remark the biological bahaviour of hign-risk NMIBC. The presence of CTC is an independent prognostic factor in patients with T1G3 bladder cancer and in the future could be an important parameter to evaluate. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e430 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gian Maria Busetto Roma, Italy More articles by this author Arianna Petracca Roma, Italy More articles by this author Chiara Nicolazzo Roma, Italy More articles by this author Paola Gazzaniga Roma, Italy More articles by this author Vincenzo Gentile Roma, Italy More articles by this author Ettore De Berardinis Roma, Italy More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...